RSPI — Respirerx Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.46m
- $4.60m
Annual cashflow statement for Respirerx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -2.59 | -2.12 | -4.3 | -3.14 | -2.1 |
| Depreciation | |||||
| Non-Cash Items | 0.317 | 0.19 | 1.25 | 0.357 | 0.49 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 1.85 | 1.44 | 2.54 | 1.83 | 1.47 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -0.427 | -0.488 | -0.513 | -0.956 | -0.144 |
| Financing Cash Flow Items | — | -0.03 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.376 | 0.471 | 0.497 | 0.957 | 0.143 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.052 | -0.017 | -0.016 | 0.001 | -0.001 |